SCHEMBL10102885

SCHEMBL10102885

CC(C)(C)C(=O)CN1CCN(C(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
KCNH2 Q12809 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
UGT8 Q16880 1/20 0.32
SIGMAR1 Q99720 2/20 0.32
TSHR P16473 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
CACNA1H O95180 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4086161 0.89 ALDH1A1 (0.54) ALDH1A1POLBCYP3A4CYP2D6PKM
SCHEMBL6840504 0.81 ALDH1A1 (0.49) ALDH1A1POLBCYP3A4CYP2D6PKM
SCHEMBL22022010 0.81 HSD17B10 (0.47) ALDH1A1SMN1; SMN2SIGMAR1HRH3CACNA1H
SCHEMBL14328665 0.81 ALDH1A1 (0.49) ALDH1A1POLBCYP3A4CYP2D6PKM
SCHEMBL24835684 0.81 HSD17B10 (0.47) ALDH1A1SMN1; SMN2SIGMAR1HRH3CACNA1H
SCHEMBL24836106 0.81 HSD17B10 (0.47) ALDH1A1SMN1; SMN2SIGMAR1HRH3CACNA1H
SCHEMBL17921358 0.81 ALDH1A1 (0.49) ALDH1A1POLBCYP3A4CYP2D6PKM
SCHEMBL22354451 0.81 ALDH1A1 (0.49) ALDH1A1POLBCYP3A4CYP2D6PKM
SCHEMBL10254329 0.81 HSD17B10 (0.47) ALDH1A1SMN1; SMN2SIGMAR1HRH3CACNA1H
SCHEMBL10261319 0.81 ALDH1A1 (0.49) ALDH1A1POLBCYP3A4CYP2D6PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-08-17 US disclosed
US-20230120619-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF GILEAD SCIENCES, INC. 2023-04-20 US disclosed
US-8841324-B2 Heterocyclic compounds as autotaxin inhibitors MERCK PATENT GMBH (DE) 2014-09-23 US disclosed
US-20120015959-A1 HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF TIE1, TEK, KDR ALDH1A1 2673/4885POLB 2678/4885CYP3A4 4809/4885
US-20230120619-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF IRAK1, IRAK2, IRAK4 ALDH1A1 1632/4885POLB 3123/4885CYP3A4 3686/4885
US-20120015959-A1 HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS ENPP2, HAX1, MTX1 ALDH1A1 4564/4885POLB 4069/4885CYP3A4 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.